Factors for arboviral seropositivity in children in Teso South Sub County, Kenya

Factors for arbovirus seropositivity in children

Authors

Mary Inziani[1*], Jane Kilonzo[2], Marthaclaire Kerubo[2], Sylvia Mango[3], Mary Kavurani[2], Allan Ndirangu[2], Elizabeth Njeri[2], Diuniceous Oigara[3], Sylvester Ayoro[3], Shingo Inoue[4,5], Kouichi Morita[5], and Matilu Mwau[2,3]

Affiliations

[1]Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya

[2]KEMRI Laboratory for Molecular Biology, Kenya Medical Research Institute, Nairobi, Kenya

[3]Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Alupe, Kenya

[4]Nagasaki University Africa Research Station, Nairobi, Kenya

[5]Nagasaki University Institute of Tropical Medicine, Nagasaki, Japan

[*]To whom all correspondence should be addressed

E-mail: mmuyeku@kemri.go.ke; inzianimatilu@gmail.com (MI)

Abstract

Background: Arboviruses like Yellow Fever Virus (YFV), Dengue Virus (DENV), Chikungunya Virus (CHIKV), and West Nile Virus (WNV) frequently cause outbreaks in sub-Saharan Africa. Identifying risk factors in children can improve diagnosis, treatment, and prevention strategies. This study identified factors associated with seropositivity to YFV, DENV, CHIKV and WNV among children in Teso South Sub-County, Western Kenya.

Methods: This survey involved 656 children aged 1 to 12 years, enrolled at two health facilities. Socio-demographic, environmental, behavioral, and medical information was collected via questionnaire. Serological screening for antibodies to YFV, DENV, CHIKV, and WNV was performed using Indirect Enzyme-Linked Immunosorbent Assays. Collected data was summarised using descriptive statistics. Factors associated with seroprevalence were examined using multinomial logistic regression.

Results: Overall, 27.7% of children were seropositive for at least one arbovirus: 15.7% for DENV, 9.6% for WNV, 5.6% for CHIKV, and 4.4% for YFV. Factors associated with any arbovirus were: female gender, age 6–9 and 9-12 years, non-parent primary caregiver, and use of unknown bed nets brand ($p<0.05$).YFV seropositivity was not associated with any of the risk factors, while DENV was associated with female gender and age 6-9 years ($p<0.05$). CHIKV was associated with use of insect repellents and not using any mosquito bed nets. WNV seropositivity was significantly higher in all children aged above 3 years, those who lived in town/urban areas, use of olyset, supanet and unknown bed nets and in those who lived in houses roofed with tiles and iron sheets ($p<0.05$).

Conclusion: Arbovirus exposure among children is influenced by age, female gender, non-parental primary care giver, failure to use mosquito bed nets, type of bed net, use

of insect repellents, and house roofing material. Interventions targeting housing improvements, education on bed net and mosquito repellent use, and environmental mosquito control can reduce infection risks in endemic areas.

Key words: Arboviruses, Children, Yellow Fever, Chikungunya, Dengue, West Nile, Seropositivity, risk factors, associated factors, Kenya

Author Summary

Yellow fever, dengue, chikungunya, and West Nile are arboviruses transmitted to humans through mosquito bites. They are prevalent in sub-Saharan Africa and often affect children. However, the associated factors for these infections in children are not well understood, yet identifying these factors is crucial for early diagnosis, appropriate treatment, and effective prevention. In this study, we aimed to identify some of the factors associated with these infections among children in Western Kenya.

We enrolled 656 children, aged 1 to 12 years, who sought healthcare at Alupe Sub-County Hospital and KEMRI Alupe Clinic in Teso Sub-County. Data on socio-demographic, behavioural, environmental, and clinical factors were collected using a structured questionnaire. Blood samples were collected and tested for antibodies to yellow fever, dengue, chikungunya, and West Nile viruses.

Among the 656 participants, 182 (27.7%) were seropositive for at least one of the four viruses: 29 (4.4%) for yellow fever, 102 (15.7%) for dengue, 36 (5.6%) for chikungunya, and 62 (9.6%) for West Nile virus. Our analysis revealed several factors that were associated with arboviral infections, including age, gender, type of primary care giver, mosquito net usage and type, other mosquito control practices and house roof design.

These factors all have an in common an increased risk of mosquito bites. Our study highlights the potential for community-based interventions targeting housing improvements, education on bed net and mosquito control measures to mitigate transmission of these infections in endemic areas of Kenya.

Introduction

Arthropod-borne viruses (arboviruses), such as Chikungunya (CHIKV), Yellow Fever (YFV), Dengue Virus (DENV), and West Nile Virus (WNV), are transmitted to humans primarily by mosquitoes. *Aedes species* are the main vectors for CHIKV, YFV and DENV, while WNV is transmitted by mainly by *Culex species* (1-9). These viruses affect both adults and children, causing significant morbidity worldwide (10, 11), and are responsible for frequent outbreaks, with many emerging and re-emerging in sub-Saharan Africa(12, 13). Kenya, in particular, has reported several arboviral outbreaks in recent years (4, 6, 7, 14-16). Children in endemic areas are especially vulnerable to these infections due to their developing immune systems, making them more susceptible to severe disease outcomes (17).

Arboviral infections often present with non-specific symptoms, including fever, jaundice, swollen lymph nodes (17), neuro-invasive disease (8, 18), joint inflammation (19), and rashes (20), which can make clinical diagnosis challenging. In sub-Saharan Africa, arboviral infections frequently go undiagnosed and unreported (21), as febrile illnesses are commonly misdiagnosed as malaria, typhoid, or other bacterial infections (8, 22). In regions with limited diagnostic resources, malaria-negative fevers are often treated presumptively with antimalarials or antibiotics, further complicating accurate diagnosis and management (23).

Despite the high burden of arboviral diseases and their significant impact on public health in Kenya, there is limited research on the prevalence, epidemiology, and associated factors for these infections in children. A few studies have attempted to document the magnitude of arbovirus infections or identified key selected factors in this population (10, 21, 24-30). This study aims to fill this gap by exploring the selected factors associated with seropositivity to YFV, DENV, CHIKV, and WNV among

104 children in Teso South Sub-County, Western Kenya. Understanding these selected
105 factors is critical for improving early diagnosis, treatment, and the implementation of
106 effective preventive measures in affected communities.

107

108 Materials and methods

109 Study design and setting

110 This hospital-based cross-sectional study was conducted between August 2010 and
111 February 2011 in Teso Sub-County, Western Kenya. We assessed the selected
112 factors for seropositivity to YFV, DENV, CHIKV, and WNV among children aged 1 to
113 12 years. A total of 656 children were recruited from those seeking health services at
114 Alupe Sub-County Hospital and KEMRI Alupe Clinic.

115 Data on socio-demographic, environmental, and clinical factors were collected using
116 a structured questionnaire. Additionally, participants' clinical records and immunization
117 cards were reviewed when available.

118 Seropositivity Testing

119 Approximately 2.5 mL of venous blood was collected from each participant for antibody
120 testing. Virus-specific IgA/IgM/IgG Sero complex antibodies to YFV, DENV, CHIKV,
121 and WNV were detected using an in-house Indirect Enzyme-Linked Immunosorbent
122 Assay (ELISA) method, based on protocols described by Igarashi et al. (31, 32) with
123 minor modifications to suit local laboratory conditions (33). The assay did not
124 differentiate between the specific antibody subtypes - IgA, IgM or IgG. The optical
125 density (OD) of each sample was measured at 492 nm using an ELISA plate reader,
126 within 20 minutes of adding the stop solution. Virus-specific OD was calculated as the
127 difference between the mean OD of virus-coated wells and the mean OD of PBS-

128 coated wells. A sample was considered seropositive if the OD was greater than 1.0.
129 In cases where the blood volume was insufficient, priority for testing was given to YFV,
130 followed by DENV2, CHIKV, WNV, DENV1, and DENV3, in that order.

131 Statistical Analysis

132 The primary outcome of the study was seropositivity to YFV, DENV, CHIKV, and WNV,
133 measured as the presence of IgA/IgM/IgG antibodies. Seropositivity rates for each
134 virus, as well as overall seropositivity rates, were calculated. Descriptive statistics
135 were used to summarize socio-demographic, clinical, and environmental variables.

136 Sociodemographic, clinical, and environmental factors were assessed for their
137 association with arbovirus seropositivity. Predictor variables included age, sex, school
138 attendance, vaccination status, caregiver characteristics, and behavioural, clinical,
139 and environmental factors.

140 Since this was a cross-sectional study, we used Prevalence Ratio (PR) to
141 conservatively estimate the strength of the association between different factors and
142 arbovirus seroprevalence. PR and the associated 95% confidence intervals (CIs) were
143 determined using Generalized Linear Model (glm) with the link (probit) function in
144 Stata. Variables with a $p < 0.20$ in univariate analysis (Unadjusted PRs - UPR) were
145 included in the multivariate analysis model and adjusted prevalence ratios (aPR) for
146 each arbovirus determined. All statistical analyses were performed using Stata/SE
147 version 17.0 for Mac (StataCorp, College Station, Texas, USA), with statistical
148 significance set at $p \leq 0.05$.

149

150 # Ethical Statement

151 This study was approved by the ethical review committee of Kenyatta National
152 Hospital – University of Nairobi Ethics and Research Committee (P108/03/2010).
153 Informed written consent was obtained from all caregivers, and verbal assent was
154 obtained from children above seven years of age before participating in the study.
155 Written parental consent was obtained for all children below years two years. The
156 study was conducted in line with the requirements of the Helsinki Declaration of 1975,
157 as revised in 2000.

158

159 # Results

160 A total of 656 participants were recruited, consisting of 316 (48.2%) males and 340
161 (51.8%) females. All participants were successfully screened for YFV and DENV
162 serotype 2. Due to insufficient sample volumes, varying numbers of participants were
163 screened for WNV (n=649), CHIKV (n=649), DENV serotype 1 (n=368), and DENV
164 serotype 3 (n=203). Participant characteristics have been previously reported (33) and
165 summarized below (Table 1).

166 **Table 1: Demographic features and frequency of exposures of the study**
167 **population to anti-arbovirus IgA/IgM/IgG Sero complex antibodies**

Participant characteristics	Total population n (%)	Any arbovirus positive n (%)	YFV Positive n (%)	Any DENV Positive n (%)	CHIK positive n (%)	WNV positive n (%)
Gender (n=656)						
Male	316 (48.2)	74 (23.4)	11 (3.48)	35 (11.1)	14 (4.5)	29 (9.3)
Female	340 (51.8)	**108 (31.8)**[c]	18 (5.29)	**68 (20.0)**[c]	22 (6.5)	33 (9.8)
Age group (Years) (n=654)						
1 - 3	267 (40.8%)	54 (20.2)	16 (5.99)	35 (13.1)	10 (3.8)	10 (3.8)
>3 - 6	202 (30.9%)	57 (28.2)	10 (4.95)	24 (11.9)	11 (5.5)	27 (13.4)
>6 - 9	92 (14.1%)	31 (33.7)	2 (2.17)	**23 (25.0)**[d]	4 (4.5)	11 (12.4)
>9 - 12	93 (14.2%)	**39 (41.9)**[d]	1 (1.08)	20 (21.5)	**11 (12.2)**[d]	**14 (15.6)**[d]
KEPI Vaccinated (n=656)						
No	14 (2.1)	6 (42.9)	0 (0.0)	3 (21.4)	1 (8.3)	**4 (33.3)**[e]
Yes	642 (97.9)	176 (27.4)	29 (4.5)	100 (15.6)	35 (5.5)	58 (9.1)
KEPI Vaccines completed (n= 643)						
No	92 (14.3)	27 (29.3)	2 (2.17)	13 (14.1)	**10 (10.9)**[f]	9 (9.8)
Yes	551 (85.7)	148 (26.9)	27 (4.9)	85 (15.4)	23 (4.2)	52 (9.4)
Yellow fever vaccinated (n=655)						
No	644 (98.3)	181 (28.1)	29 (4.50)	103 (16.0)	36 (5.7)	61 (9.6)
Yes	11 (1.7)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (9.1)

School Attendance (n=656)						
None	347 (52.9)	81 (23.3)	19 (5.5)	46 (13.3)	16 (4.6)	24 (6.9)
In school	309 (47.1)	101 32.7)[g]	10 (3.2)	57 (18.5)	20 (6.6)	**38 (12.6)[g]**
Usual Residence (n=656)						
Town/urban	115 (17.5)	33 (28.7)	4 (3.5)	16 (13.9)	5 (4.4)	**19 (16.7)[h]**
Village/Rural	532 (81.1)	148 (27.8)	25 (4.7)	87 (16.4)	30 (5.7)	43 (8.2)
Both rural and urban	9 (1.4)	1 (11.1)	0 (0.0)	0 (0.0)	1 (11.1)	0 (0.0)
Primary Care giver (n=655)						
Parent	590 (90.1)	151 (25.6)	25 (4.2)	88 (14.9)	29 (5.0)	50 (8.9)
Grand parent	39 (5.9)	14 (35.9)	3 (7.7)	7 (18.0)	3 (8.3)	4 (11.1)
Other	26 (4.0)	**16 (61.5)[i]**	1 (3.9)	7 (26.9)	**4 (15.4)[i]**	**7 (26.9)[i]**

[c] Significant difference between the sexes (p<0.01) by chi square test.
[d] Significant difference between the age groups (p<0.01) by chi square test
[e] Significant difference between those who did not get any routine vaccinations (p=0.005) by chi square test
[f] Significant difference between the who did not complete routine vaccinations (p=0.005) by chi square test
[g] Significant difference between school attendance and none (p = 0.014) by chi square test
[h] Significant difference between residences (p = 0.012) by chi square test
[i] Significant difference between the primary caregiver (p<0.05) by chi square test

Factors associated with seropositivity to any Arbovirus

Univariate and multivariate analyses of the selected factors associated with seropositivity to any arbovirus are presented in Table 2. Among the study participants, 182 (27.7%) were seropositive for at least one of the four arboviruses. Female participants had a significantly higher seroprevalence compared to males (UPR 1.29, 95% CI 1.05-1.58, p=0.017); this difference was also seen in the multivariate model (aPR 1.27, 95% CI 1.02-1.59, p=0.035).

Table 2: Univariate and multivariate regression analysis of selected factors for Any Arbovirus seropositivity

Table 2: Univariate and Multivariate Logistic Regression for any arbovirus							
Characteristic	**Number (%)**	**Univariate Analysis**			**Multivariate Analysis**		
		UPR	**95% CI**	**p-value**	**aPR**	**95% CI**	**p-value**
Sex	656						
Male	316(48.17)	Ref	-				
Female	340(51.83)	1.29	1.05, 1.58	0.017**	1.27	1.02, 1.59	0.035**
Age Category	654						
1-3y	228(34.86)	Ref	-				
3-6y	211(32.26)	1.25	0.96, 1.63	0.091	1.13	0.85, 1.49	0.402
6-9y	99(15.14)	1.63	1.19, 2.24	0.002**	1.43	1.02, 2.01	0.037**
9-12y	82(12.54)	1.8	1.29, 2.51	0.001**	1.48	1.01, 2.16	0.042**
Kepi card completed	651						
No	132 (20.28)	Ref					
Yes	519 (79.72)	0.77	0.60, 0.98	0.037**	1.03	0.77, 1.37	0.833
Primary Carer	655						
Parent	590(90.08)	Ref	-				
Grandparent	39(5.95)	1.34	0.88, 2.04	0.167	1.22	0.76, 1.95	0.411
Other	26(3.97)	2.58	1.56, 4.27	0.000**	1.94	1.11, 3.38	0.020**
Mosquito Control Measures	655						
None	512(78.17)	Ref	-				
Repellents	73(11.15)	1.25	0.91, 1.72	0.164	1.16	0.81,1.65	0.413
Sprays	70(10.69)	1.16	0.84, 1.61	0.376	0.99	0.68,1.44	0.957
Type of Bed net	656						
Permanet	290(44.21)	Ref					

Mixed	51(7.77)	1.16	0.77, 1.74	0.482	1.04	0.68, 1.59	0.872
None	14(2.13)	1.55	0.78, 3.10	0.214	1.45	0.65, 3.25	0.360
Olyset	211(31.16)	1.62	1.17, 1.89	0.001**	1.28	0.99, 1.67	0.063
Supanet	67(10.21)	1.21	0.84, 1.73	0.306	0.98	0.64, 1.51	0.941
Unknown	23(3.51)	2.64	1.54, 4.53	0.000**	2.28	1.24, 4.17	0.008**
Type of Roof	656						
iron sheets	387(58.99)	Ref	-				
grass	228(34.76)	0.86	0.69, 1.07	0.176	0.87	0.68,1.11	0.258
iron sheets/tiles	41(6.25)	1.41	0.94, 2.13	0.096	1.22	0.77, 1.93	0.386
Feeling Sick	656						
No	379(57.77)	Ref	-				
Yes	277(42.23)	0.8	0.65, 0.99	0.036**	0.95	0.74,1.22	0.668
Rash	656						
No	451(68.75)	Ref	-				
Yes	205(31.25)	1.26	1.01, 1.57	0.038**	1.07	0.79,1.45	0.658
Past Rash	656						
No	563(85.82)	Ref	-				
Yes	93(14.18)	1.21	0.91, 1.61	0.199	0.93	0.63,1.38	0.738
Abbreviations: CI = Confidence Interval, UPR = Unadjusted Prevalence Ratio, aPR = Adjusted Prevalence Ratio, **= p<0.05							

In the univariate model, children aged 6-9 years (UPR 1.63, 95% CI 1.19-2.24, p=0.002) and 9-12 years (UPR 1.8, 95% 1.29-2.51, p=0.001) showed significantly higher seroprevalence compared to the reference group aged 1-3 years. In the multivariate model, children aged 6-9 years had an increased rate of seropositivity (aPR 1.43, 95% CI 1.02-2.01, p=0.037), while those aged 9-12 years had an aPR of 1.48 (95% CI 1.01-2.16, p=0.042) when compared to children aged 1-3 years.

Children with "Other" caregivers had a higher rate of seropositivity compared to those with parental caregivers (UPR 2.58, 95% CI 1.56-4.27, p<0.001) in univariate regression; this finding was replicated in the multivariate model (aPR 1.94, 95% CI 1.11-3.38, p=0.020).

The rate of seropositivity was also higher in children using Olyset (UPR 1.62, 95% CI 1.17-1.89, *p*=0.001) or unbranded/unknown bed nets (UPR 2.64, 95% CI 1.54-4.53, *p*<0.001) compared to those using Permanet nets. The association between

unbranded nets and seroprevalence was replicated in the multivariate model (aPR 1.24, 95% CI 1.24-4.17, p=0.008).

Presenting with a completed KEPI card was associated with lower seroprevalence to any arbovirus (UPR 0.77, 95% CI 0.60-0.98, p=0.037. So also, was presenting with "feeling sick" (UPR 0.8, 95% CI 0.65-0.99, p= 0.036). None of these was replicated in multivariate analysis.

Finally, presenting with a rash was associated with higher seroprevalence (UPR 1.26, 95% CI 1.06-1.57, p=0.038). This was not seen in the multivariate model.

Factors associated with Seropositivity to Yellow Fever, Dengue, Chikungunya and West Nile Viruses

Factors associated with seropositivity to YFV, DENV, CHIKV and WNV are presented in Tables 3, 4, 5 and 6 respectively.

Yellow Fever Virus

No positive or negative associations were noted either in the univariate or multivariate models of factors for YFV seroprevalence (Table 3).

Table 3: Univariate and Multivariate Logistic Regression for YFV seroprevalence

Table 3: Univariate and Multivariate Logistic Regression for YFV seroprevalence							
Characteristic	**Number (%)**	**Univariate Analysis**			**Multivariate Analysis**		
		UPR	**95% CI**	**p-value**	**aPR**	**95% CI**	**p-value**
Age Category	654						
1-3y	228(34.86)	Ref	-				
3-6y	211(32.26)	0.87	0.58, 1.30	0.491	1.02	0.64, 1.63	0.936
6-9y	99(15.14)	1.03	0.64, 1.65	0.899	1.51	0.72, 3.17	0.271
9-12y	82(12.54)	0.51	0.23, 1.13	0.098	0.76	0.29, 2.01	0.578
Attend school	656						
No	347(52.90)	Ref					

Yes	309(47.10)	0.78	0.55, 1.11	0.164	0.87	0.49, 1.54	0.630
Kepi card completed	651						
No	132(20.28	Ref					
Yes	519(79.72)	1.43	0.86, 2.37	0.167	1.45	0.86, 2.44	0.161
Waterbodies	656						
No	385(58.69)	Ref					
Yes	271(41.31)	0.69	0.48, 1.01	0.055	0.69	0.47, 1.03	0.071
Abbreviations: CI = Confidence Interval, UPR = Unadjusted Prevalence Ratio, aPR = Adjusted Prevalence Ratio, **= p<0.05							

Dengue virus

Females had higher rate of seropositivity than males to any of the three DENV serotypes (UPR 1.46, 95% CI 1.15-1.86, p=0.002) in univariate analysis; this was confirmed in the multivariate model (aPR 1.62, 95% CI 1.24-2.10, p<0.001). Dengue antibody prevalence was higher in children aged 6-9 years (UPR 1.54, 95% CI 1.10-2.16, p=0.012) compared to those aged 1-3 years; this was also seen in the multivariate model (aPR 1.80, 95% CI 1.23-2.64, p=0.03). Although no association was noted in the univariate model DENV antibody seroprevalence was higher in children aged 9-12 years compared to those aged 1-3 years (aPR 1.54, 95% CI 1.00-2.38, p=0.050) in the multivariate model. (Table 4).

Table 4: Univariate and Multivariate Logistic Regression for DENV seroprevalence

Table 4: Univariate and Multivariate Logistic Regression for DENV seroprevalence							
Characteristic	**Number (%)**	**Univariate Analysis**			**Multivariate Analysis**		
		UPR	**95% CI**	**p-value**	**aPR**	**95% CI**	**p-value**
Sex	656						
Male	316(48.17)	Ref	-				
Female	340(51.83)	1.46	1.15, 1.86	0.002**	1.62	1.24, 2.10	0.000**
Age Category	654						
1-3y	228(34.86)	Ref	-				
3-6y	211(32.26)	0.85	0.63, 1.16	0.309	0.91	0.65,1.27	0.592
6-9y	99(15.14)	1.54	1.10, 2.16	0.012**	1.8	1.23, 2.64	0.003**

9-12y	82(12.54)	1.38	0.96, 1.99	0.082	1.54	1.00, 2.38	0.050**
KEPI card completed	651						
No	132(20.28	Ref					
Yes	519(79.72)	0.69	0.53, 0.90	0.007**	0.95	0.68, 1.32	0.747
Primary Carer	655						
Parent	590(90.08)	Ref	-				
Grandparent	39(5.95)	1.13	0.70, 1.82	0.614	1.23	0.73, 2.09	0.428
Other	26(3.97)	1.53	0.90, 2.60	0.117	1.48	0.77, 2.84	0.237
Bednet brand	656						
Permanet	290(44.21)	Ref					
Mixed	51(7.77)	0.83	0.51, 1.34	0.447	0.69	0.41, 1.15	0.150
None	14(2.13)	1	-	-	1	-	-
Olyset	211(31.16)	1.15	0.88, 1.49	0.299	1.08	0.80, 1.46	0.628
Supanet	67(10.21)	0.71	0.45, 1.12	0.141	0.78	0.43, 1.41	0.407
Unknown	23(3.51)	1.06	0.57, 1.99	0.848	0.95	0.46, 1.96	0.899
Type of Roof	656						
Iron sheets	387(58.99)	Ref	-				
Grass thatch	228(34.76)	0.77	0.59, 1.00	0.047**	0.84	0.63, 1.12	0.228
Iron sheets/tiles	41(6.25)	0.97	0.60, 1.56	0.904	1.12	0.65, 1.93	0.672
Eaves	656						
No	611(93.14)	Ref					
Yes	45(6.86)	0.48	0.25, 0.93	0.029**	0.68	0.33, 1.40	0.295
Waterbodies	656						
No	385(58.69)	Ref					
Yes	271(41.31)	0.77	0.61, 0.98	0.037**	0.79	0.58, 1.07	0.127
Past Rash	656						
No	563(85.82)	Ref	-				
Yes	93(14.18)	0.77	0.53, 1.10	0.150	0.68	0.44, 1.06	0.088
Sore throat	656						
No	611(93.14)	Ref					
Yes	45(6.86)	0.59	0.33, 1.06	0.076	0.41	0.22, 0.79	0.008**
Abbreviations: CI = Confidence Interval, UPR = Unadjusted Prevalence Ratio, aPR = Adjusted Prevalence Ratio, **= p<0.05							

Presenting with a fully completed KEPI card (UPR 0.69, 95% CI 0.53-0.90, p=0.007), living in a grass thatched house as opposed to an iron sheets-roofed house (UPR 0.77, 95% CI 0.59-1.00, p=0.047), living in a house that had eaves (UPR 0.48, 95% CI 0.25-0.93, p=0.029), and living near water bodies (UPR 0.77, 95% CI 0.61-0.98,

241 p=0.037) were all associated with lower DENV seroprevalence, but this effect was not
242 replicated in the multivariate model (p>0.05).
243

244 Chikungunya Virus

245 For CHIKV, those in “Upper Primary School” had a significantly higher seroprevalence
246 in univariate analysis (UPR 1.56, 95% CI 1.00-2.44, p=0.049); in the multivariate
247 model, this was not seen. Children whose caregiver was "Other" had higher CHIKV
248 seroprevalence compared to those with parental caregivers (UPR 1.8 95% CI 1.02-
249 3.45, p=0.043); this association was not seen in multivariate analysis (p>0.05). (Table
250 5).
251

252 **Table 5: Univariate and Multivariate Logistic Regression for CHIKV seroprevalence**
253

Table 5: Univariate and Multivariate Logistic Regression for CHIKV seroprevalence							
Characteristic	**Number (%)**	Univariate Analysis			Multivariate Analysis		
		PR	95% CI	p-value	PR	95% CI	p-value
Class	656						
None	346(52.74)	Ref					
Preschool	136(20.73)	1.06	0.69, 1.61	0.797	1.03	0.64, 1.67	0.886
Lower Primary	97(14.79)	1.08	0.67, 1.74	0.765	1.00	0.57, 1.77	0.937
Upper primary	76(11.59)	1.56	1.00, 2.44	0.049**	1.57	0.95, 2.57	0.076
KEPI card completed	651						
No	132(20.28	Ref					
Yes	519(79.72)	0.76	0.53, 1.10	0.150	1.43	0.70, 2.90	0.328
Kepi vaccination completed	643						
No	92(14.31)	Ref					
Yes	551(85.69)	0.61	0.41, 0.90	0.012**	0.56	0.28, 1.12	0.102
Primary Carer	655						
Parent	590(90.08)	Ref					
Grandparent	39(5.95)	1.31	0.71, 2.41	0.394	0.94	0.46, 1.92	0.866
Other	26(3.97)	1.88	1.02, 3.45	0.043**	1.57	0.84, 2.95	0.155
Mosquito control	555						
None	512(78.17)	Ref					
Repellents	73(11.15)	2.03	1.36, 3.04	0.001**	2.54	1.62, 3.98	0.000**

Sprays	70(10.69)	1.17	0.70, 1.95	0.556	1.09	0.57, 2.11	0.793
Type of Bednet	656	Ref					
Permanet	290(44.21)						
Mixed	51(7.77)	1.02	0.51, 2.01	0.965	1.13	0.54, 2.37	0.751
None	14(2.13)	2.67	1.22, 5.86	0.014**	2.5	1.03, 6.06	0.042**
Olyset	211(31.16)	1.34	0.92, 1.94	0.130	1.28	0.84, 1.93	0.248
Supanet	67(10.21)	0.9	0.46, 1.73	0.748	0.87	0.43, 1.75	0.688
Unknown	23(3.51)	2.31	1.19, 4.47	0.013**	1.9	0.92, 3.93	0.082
Type of Roof	656						
Iron sheets	387(58.99)	Ref					
Grass thatch	228(34.76)	1.38	0.99, 1.91	0.054	1.59	1.11, 2.28	0.012**
Iron sheets/tiles	41(6.25)	1.08	0.54, 2.14	0.837	0.46	0.18, 1.18	0.106
Waterbodies	656						
No	385(58.69)	Ref					
Yes	271(41.31)	1.32	0.96, 1.82	0.084	0.71	0.45, 1.11	0.131
Feeling Sick	656						
No	379(57.77)						
Yes	277(42.23)	0.64	0.45, 0.91	0.014**	0.7	0.46, 1.08	0.109
Past rash	656						
No	451(68.75)						
Yes	205(31.25)	1.55	1.05, 2.28	0.026**	1.43	0.89, 2.28	0.138
Abbreviations: CI = Confidence Interval, UPR = Unadjusted Prevalence Ratio, aPR = Adjusted Prevalence Ratio, **= p<0.05							

Children who lived in homes that used mosquito repellents had a higher seroprevalence of CHIKV antibodies when compared with those who did not (UPR 2.03, 95% CI 1.36-3.04, p=0.001); this was replicated in the multivariate model (aPR 2.54, 95% CI 1.62-3.98, p<0.001).

Those who did not sleep under any bed net had a higher CHIKV seroprevalence (UPR 2.67, 95% CI 1.22-5.86, p=0.014) when compared to those who used the brand “Permanet”. In multivariate analysis, this association was also seen (aPR 2.5, 95% CI 1.03-6.06, p=0.042). Moreover, even those who used an unknown brand of net had higher seropositivity (UPR 2.31, 95% CI 1.19-4.47, p=0.013) when compared to those who used the brand “Permanet”, but this was not seen in the multivariate model (p>0.05). Those who live in houses thatched with grass had a higher prevalence of

267 CHIKV antibodies in multivariate analysis (aPR 1.59, 95% CI 1.11-2.28, p=0.012),
268 although this was not seen in the univariate analysis.
269 Children who reported a past rash showed high CHIKV seroprevalence (UPR 1.55,
270 95% CI 1.05-2.28, p=0.026) compared to those who did not; this was not seen during
271 the multivariate analysis.
272 Those who had completed their KEPI vaccination schedule (UPR 0.61, 95% CI 0.41-
273 0.90, p=0.012), and those who presented feeling sick (UPR 0.64, 95% CI 0.45-0.91,
274 p=0.014) all showed lower CHIKV seroprevalence in univariate but not multivariate
275 analysis.
276

277 ## West Nile Virus

278 For WNV, antibody seroprevalence in those aged 3-6 (PR 1.94, 95% CI 1.31-2.88,
279 p=0.001), 6-9 (UPR 2.28, 95% CI 1.46-3.56, p<0.001) and 9-12 (UPR 2.18, 95% CI
280 1.36- 3.49, p=0.001) year age groups were significantly higher compared to those
281 aged 1-3 years. In the multivariate model the aPR was also higher for all age groups
282 when compared to 1-3 years: in those aged 3-6 it was 2.14 (95% 1.35-3.40, p=0.001),
283 in those aged 6-9 it was 2.9 (95% CI 1.56-5.40, p=0.001), while for those aged 9-12
284 years it was 2.27 (95% CI 1.19-4.34, p=0.013). (Table 6).
285

286 **Table 6: Univariate and Multivariate Logistic Regression for WNV seroprevalence**

Table 6: Univariate and Multivariate Logistic Regression for WNV seroprevalence							
Characteristic	**Number (%)**	Univariate Analysis			Multivariate Analysis		
		PR	95% CI	p-value	PR	95% CI	p-value
Age Category	654						
1-3y	228(34.86)	Ref					
3-6y	211(32.26)	1.94	1.31, 2.88	0.001**	2.14	1.35, 3.40	0.001**
6-9y	99(15.14)	2.28	1.46, 3.56	0.000**	2.9	1.56, 5.40	0.001**
9-12y	82(12.54)	2.18	1.36, 3.49	0.001**	2.27	1.19, 4.34	0.013**
Residence	656						
Village	115(17.53)	Ref					

Town	532(81.10)	1.53	1.12, 2.10	0.005**	1.50	1.02, 2.20	0.040**
Other	9(1.37)	1.00	-	-	1.00	-	-
Attend school	656						
No	347(52.90)	Ref					
Yes	309(47.10)	1.40	1.07, 1.83	0.015**	0.70	0.46, 1.09	0.113
Primary Carer	655						
Parent	590(90.08)	Ref					
Grandparent	39(5.95)	1.16	0.66, 2.04	0.600	0.75	0.38, 1.49	0.408
Other	26(3.97)	2.13	1.24, 3.64	0.006**	1.67	0.85, 3.28	0.136
Type of Bednet	656						
Permanet	290(44.21)	Ref					
Mixed	51(7.77)	1.75	0.97, 3.16	0.060	2.34	1.22, 4.50	0.010**
None	14(2.13)	3.27	1.47, 7.27	0.004**	2.42	0.74, 7.96	0.145
Olyset	211(31.16)	2.52	1.73, 3.68	0.000**	2.75	1.73, 4.35	0.000**
Supanet	67(10.21)	2.55	1.57, 4.12	0.000**	2.18	1.25, 3.80	0.006**
Unknown	23(3.51)	4.87	2.64, 8.99	0.000**	5.06	2.46, 10.41	0.000**
Type of Roof	656						
Iron sheets	387(58.99)	Ref					
grass	228(34.76)	1.12	0.83, 1.50	0.460	1.34	0.94, 1.92	0.110
Iron sheets/tiles	41(6.25)	2.43	1.55, 3.79	0.000**	1.96	1.20, 3.21	0.007**
Water bodies near house	656						
No	385 (58.68)	Ref					
Yes	271(41.31)	1.69	1.29, 2.23	0.000**	0.95	0.64, 1.40	0.779
Vegetation around the house	656						
No	411(62.65)	Ref					
Yes	245(37.35)	1.34	1.03, 1.76	0.032**	1.08	0.75, 1.56	0.681
Feeling sick	656						
No	379(57.77)	Ref					
Yes	277(42.23)	0.67	0.50, 0.90	0.007**	1.16	0.78, 1.72	0.466
Rash	656						
No	451(68.75)	Ref					
Yes	205(31.25)	1.69	1.29, 2.23	0.000**	1.31	0.83, 2.06	0.242
Past rash	656						
No	451(68.75)	Ref					
Yes	205(31.25)	1.64	1.17, 2.29	0.004**	1.24	0.77, 1.98	0.375
Sore throat	656						
No	563(85.82)	Ref					
Yes	93(14.18)	1.38	0.87, 2.20	0.180	1.09	0.64, 1.83	0.757
Abbreviations: CI = Confidence Interval, UPR = Unadjusted Prevalence Ratio, aPR = Adjusted Prevalence Ratio, **= p<0.05							

287

Living in a town/urban area was associated with a higher seroprevalence of WNV (UPR 1.53, 95%CI 1.12-2.10, p=0.005) when compared with living in the village, and this was replicated in the multivariate model (aPR 1.50, 95% CI 1.02-2.20, p=0.040). Attending school was also associated with higher seroprevalence (UPR 1.40, 95% CI 1.07-1.83, p=0.015) but only in the univariate model.

Those children whose caregiver was "Other" had a higher seroprevalence of WNV antibodies compared to those with parental caregivers (UPR 2.13, 95% CI 1.24-3.64, p=0.006) but this was not replicated in the multivariate model.

WNV seroprevalence was also higher in children using no mosquito net (UPR 3.27, 95% CI 1.47-7.27, p=0.004), “Olyset” (PR 2.52, 95% CI1.73-3.68, p<0.001), “Supanet” (UPR 2.55, 95% CI 1.57-4.12, p=0.001), or unknown brands of bed nets (UPR 4.87, 95% CI 2.64-8.99, p<0.001) when compared to those using “Permanet” nets in univariate analysis. These associations remained significant in the multivariate model (p<0.05) except for those using no net at all (aPR 2.42 95%CI 0.74-7.96, p=0.145).

Those living in houses that were roofed with a mix of iron sheets and tiles had higher WNV seroprevalence (UPR 2.43, 95% CI 1.55-3.79, p<0.001) compared to those living in houses roofed with iron sheets only. This was affirmed in the multivariate model (aPR 1.96, 95% CI 1.20-3.21, 0.007).

Having water bodies near the house (UPR 1.69, 95% CI 1.29-2.23, p<0.001), vegetation around the house (UPR 1.34, 95% CI 1.03-1.76, p=0.032), an active rash (UPR 1.69, 95% CI 1.29-2.23, p=0.001), or a past rash (UPR 1.64, 95% CI 1.17-2.29, p=0.004) were all associated with higher seroprevalence of WNV but this was not seen in the multivariate model.

Those who presented feeling sick (UPR 0.67, 95% CI 0.50-0.90, p=0.007) all had lower WNV seroprevalence in univariate but not in multivariate analysis.

313 # Discussion

314 In this cross-sectional study conducted in Western Kenya, we identified several
315 factors: age, female gender, non-parental primary care giver, urban residence,
316 mosquito net usage, and bed net type, use of insect repellents, and house roofing
317 material, that are significantly associated with exposure to arboviral infections.

318 Our findings suggest that females exhibited a higher rate of seropositivity to dengue
319 virus (DENV). This finding has been demonstrated in other studies. This could be
320 attributed to behavioural and environmental factors. *Aedes aegypti*, the primary vector
321 for DENV, predominantly resides and bites in outdoor environments in daytime, such
322 as in garden vegetation, but can also reside and bite in indoor environments such as
323 kitchens and bedrooms. The mosquito bites exposed areas such as the lower legs,
324 ankles, and arms. In Western Kenya, women are often more engaged in outdoor
325 activities such as gardening, fetching water or firewood, and indoor chores such as
326 cooking, which puts them at greater risk of mosquito bites compared to men.
327 Additionally, they are less likely to wear protective clothing while performing these
328 activities. Similar patterns have been observed in other sub-Saharan African studies,
329 where women's involvement in both domestic and outdoor activities increase their
330 exposure to daytime-biting mosquitoes (23, 27–29).

331 In this study, seropositivity for any arbovirus increased with age, similar to other
332 studies that have found an association between increasing age and arbovirus
333 exposure(11, 34). Children aged 3–9, 6-9 and 9-12 years had a higher rate of
334 seropositivity for WNV, while those aged 6–9 years showed significantly higher
335 seropositivity to DENV compared to younger children (1–3 years). *Culex* mosquitoes,
336 which transmit WNV, breed in stagnant water near human habitation, and are most
337 active and bite humans primarily at dusk and dawn. They are also known to bite
338 throughout the night. In Western Kenya, older children often play outdoors, particularly

339 during these peak *Culex* mosquito activity periods, and frequently interact with water
340 sources, such as stagnant pools, broken pots and discarded containers and used tires.
341 School attendance, which involves outdoor activities during these periods, likely
342 contributes to the higher exposure to both *Aedes* mosquitoes during the day and *Culex*
343 mosquitoes at dawn and dusk (30, 31, 32, 33).
344 Children whose primary caregivers were not their parents or grandparents had a
345 higher seropositivity to any arbovirus, likely reflecting the protective roles that parents
346 and grandparents play in limiting outdoor exposure to mosquitoes and ensuring
347 children wear appropriate clothing.
348 We also observed a higher prevalence of WNV in individuals residing in homes with
349 iron sheet and tile roofs. Water collected from iron sheet and tile roofs in rainwater
350 barrels, catch basins, storm drains and others provide relatively clean water, an ideal
351 habitat for breeding *Culex* mosquitoes, with the tiles also offering a shaded and humid
352 environment that fosters the development of mosquito larvae in the small water pools
353 that form between them. Moreover, the tiles serve as shelter for adult mosquitoes
354 during their less active daytime hours. In contrast, grass-thatched roofs were
355 associated with a higher seropositivity to chikungunya virus (CHIKV). This may be due
356 to the use of pots and gourds for storage of water in these homes, which are likely to
357 harbour *Aedes* mosquitoes, as these mosquitoes tend to rest in the inner linings of
358 such containers.
359 Urban residence was also associated with higher WNV seroprevalence, which can be
360 attributed to the increased abundance of *Culex* mosquitoes in urban areas, where
361 stagnant water from drainage systems, old tires, puddles, and other waste provides
362 breeding sites. This finding agrees with some studies that have correlated urbanization
363 with WNV disease(35, 36).
364 An intriguing finding was that the use of insect repellents was associated with a higher
365 seropositivity to CHIKV compared to using sprays or not using any repellent. This may

366 suggest that some repellents are less effective against *Aedes* mosquitoes, and tend
367 to be used during non-peak *Aedes* mosquito bite times, possibly providing users with
368 a false sense of protection. Additionally, individuals using repellents may be more
369 likely to reside in thatched-roof homes, which are associated with higher seropositivity
370 to CHIKV, or may have inadequate mosquito protection during daytime hours when
371 *Aedes* mosquitoes predominantly bite.
372 Interestingly, although mosquito nets are effective in preventing malaria, most brands
373 did not significantly reduce WNV seroprevalence. In fact, when compared to
374 Permanet, all other brands were significantly less effective in reducing WNV exposure,
375 which corroborates previous findings(37). Given that *Culex* mosquitoes are active at
376 dusk and dawn, mosquito nets may have limited efficacy against them. Regarding
377 CHIKV, the use of unknown brands of mosquito nets was notably detrimental. The
378 reduced effectiveness of mosquito nets could be attributed to factors such as wear
379 and tear or insufficient insecticide treatment, which is often seen in well-established
380 brands, underscoring the need for alternative prevention strategies. In addition, *Aedes*
381 *Aegypti,* predominantly bite outdoors, during daytime, when bed nets are unlikely to
382 be of help.
383 Clinical symptoms such as fever and rash were evaluated for their association with
384 seropositivity, but only “feeling sick”, and a rash were significantly linked to arbovirus
385 seropositivity in the univariate, but not in the multivariate models: “Feeling Sick” was
386 associated with a decrease in any arbovirus, CHIKV and WNV seropositivity, while a
387 rash was associated with increased risk of any arbovirus, CHIKV and WNV
388 seropositivity. However, the cross-sectional design of our study, and the lack of
389 differentiation between antibody subtypes (hence no differentiation between recent
390 and past arbovirus infections) limits our ability to establish causality, as other
391 conditions with overlapping symptoms, such as malaria and typhoid, could confound

392 these results, and current symptoms could not be attributed to active arbovirus
393 infection.
394 We detected antibodies in infants and young children aged 1-3y. Whereas maternal
395 IgA and IgG antibodies are transmitted via breastfeeding and may influence
396 seropositivity results in breastfeeding infants, these antibodies decline within a year of
397 cessation of breastfeeding(38). Nonetheless, our study was not designed to delineate
398 seropositivity induced by mosquito bites from that induced by maternal antibodies.
399 Ergo, we did not attribute the clinical symptoms to ongoing arbovirus infection in this
400 age group.
401 Some factors were significantly associated with arbovirus seropositivity in the
402 univariate analysis, but were not significant in the multivariate model. For instance,
403 having a completed KEPI card, reporting “feeling sick”, having a rash and olyset bed
404 net were associated with any arbovirus; completed KEPI card, eaves, and water
405 bodies near the house with DENV; attending upper primary school, completed
406 vaccinations, “Other” carer givers, unknown bed nets, feeling sick and a past rash with
407 CHIKV; while attending school, vegetation and water bodies near the house; “Other”
408 care givers, not using bed nets, feeling sick, an ongoing and a past rash were
409 associated with WNV in the univariate analysis. None of these were replicated in the
410 multivariate analysis. This may be explained by confounding by other variables in the
411 multivariate model.
412

413 # Conclusion

414 Our study highlights the significant role of sociodemographic, behavioural, and
415 environmental factors in determining exposure to arboviral infections in children in
416 Western Kenya. Age, female gender, non-parental primary care giver, failure to use
417 mosquito bed nets, type of bed net, use of insect repellents, urban residence and

house roofing material, were identified as important factors associated with arbovirus exposure among children. These factors are modifiable and may serve as targets for tailored interventions to reduce the burden of arboviral infections. Interventions targeting housing improvements, education on bed net and mosquito repellent use, and environmental mosquito control measures can help reduce the burden of arbovirus diseases in endemic areas.

Recommendations

Based on the findings of this study, we propose several interventions to reduce arboviral transmission in Western Kenya:

1. **Gender-Sensitive Prevention Programs**: Programs should be designed to address gender-specific exposure. Women, who are more likely to engage in domestic and outdoor activities that increase exposure to daytime-biting mosquitoes, could benefit from appropriate protective clothing and environmental interventions.
2. **Targeted Mosquito Control**: In addition to traditional mosquito nets, interventions should focus on mosquito repellents effective against daytime-biting mosquitoes and strategies to reduce exposure to *Aedes* mosquitoes, the primary vectors of arboviral transmission and *Culex* mosquitoes.
3. **Enhanced Vector Control in Vegetation-Dense Areas**: Given the association between dense vegetation and increased seropositivity, vector control efforts should be expanded, particularly in areas with abundant vegetation and stagnant water around homes, which provide breeding grounds for mosquitoes.
4. **Further Research on Bed net Efficacy**: Additional studies are needed to assess the effectiveness of various mosquito net brands in preventing arboviral infections, considering factors such as insecticide treatment, net durability, and the mosquito

species involved in transmission. Research should also explore alternative protective measures, including daytime repellents and environmental management of mosquito breeding sites.

By targeting these modifiable factors, it may be possible to reduce the prevalence of arboviral infections and improve public health outcomes in the region.

Study Limitations

The detection of arthropod-borne viruses using ELISA, and interpretation of the results is challenging due to cross reactivity, limiting the confidence in reported outcomes. The ELISA tests employed for this study did not differentiate between the IgA, IgM or IgG immunoglobulin classes. To mitigate this, we employed Plaque Reduction Neutralization Tests (PRNT) to confirm results whenever sample volumes allowed(33). However, due to the limited sample volumes, we could not estimate the true burden of some of the arboviruses in the study group. Additionally, as this study was hospital-based, there is a potential for selection bias, and the results cannot be extrapolated to the study population. Moreover, the use of stringent ELISA cutoff criteria, as outlined by Igarashi et al., may have excluded some samples that were actually positive. With larger sufficient sample volumes, this limitation could be addressed through PRNT.

Acknowledgements

We would like to acknowledge all the people, listed and not listed, whose contributions made this research possible. We thank Dr Toru Kubo and his team from the Department of Virology (Nagasaki University Institute of Tropical Medicine, Nagasaki, Japan), research colleagues from the Department of Paediatrics and Child Health (University of Nairobi, Kenya) and Prof. Masaaki Shimada (Nagasaki University Africa

Research Station, Nairobi, Kenya) who provided insight and expertise that greatly assisted the research.

We also wish to thank Joyce Ngoi, Minayo Chahilu, Carolyne Kirwaye, Sheila Kageha and Janet Owando (Kenya Medical Research Institute) for their technical support and Michael Obura, Evans Omao, the staff of KEMRI Alupe Clinic and Alupe Sub-County Hospital who were instrumental in the recruitment and data collection.

We would also like to thank Dr Jimmy Wafula and other staff members at Alupe Sub-County Hospital for making the research possible. We thank Dr Martin Mulinge for reviewing the manuscript in its second iteration, and Nancy Kagendi for reviewing the regression models.

The parents/guardians and the children who agreed to participate in this study deserve special thanks.

We acknowledge the financial, infrastructural and technical support accorded by Kenya Medical Research Institute, Nairobi, Kenya, and the financial and technical support offered by the Department of Virology, Nagasaki University Institute of Tropical Medicine, Nagasaki, Japan.

References

1. Manning JE, Morens DM, Kamhawi S, Valenzuela JG, Memoli M. Mosquito saliva: the hope for a universal arbovirus vaccine? The Journal of infectious diseases. 2018;218(1):7-15.

2. Braack L, Gouveia de Almeida AP, Cornel AJ, Swanepoel R, De Jager C. Mosquito-borne arboviruses of African origin: review of key viruses and vectors. Parasites & vectors. 2018;11(1):1-26.

3. Njenga MK, Nderitu L, Ledermann J, Ndirangu A, Logue C, Kelly C, et al. Tracking epidemic chikungunya virus into the Indian Ocean from East Africa. Journal of General Virology. 2008;89(11):2754-60.

4. Sang RC, Dunster L. The growing threat of arbovirus transmission and outbreaks in Kenya: a review. East African medical journal. 2001;78(12):655-61.

5. Rodrigues NCP, Daumas RP, de Almeida AS, Dos Santos RS, Koster I, Rodrigues PP, et al. Risk factors for arbovirus infections in a low-income community of Rio de Janeiro, Brazil, 2015-2016. PLoS One. 2018;13(6):e0198357.

6. Ellis EM, Neatherlin JC, Delorey M, Ochieng M, Mohamed AH, Mogeni DO, et al. A household serosurvey to estimate the magnitude of a dengue outbreak in Mombasa, Kenya, 2013. PLoS neglected tropical diseases. 2015;9(4):e0003733.

7. Tchouassi DP, Bastos AD, Sole CL, Diallo M, Lutomiah J, Mutisya J, et al. Population genetics of two key mosquito vectors of Rift Valley fever virus reveals new insights into the changing disease outbreak patterns in Kenya. PLoS Neglected Tropical Diseases. 2014;8(12):e3364.

8. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-7.

9. Barrett AD, Monath TP. Epidemiology and ecology of yellow fever virus. Advances in virus research. 2003;61:291-317.

512 10. Shah MM, Ndenga BA, Mutuku FM, Vu DM, Grossi-Soyster EN, Okuta V, et al.
513 High Dengue Burden and Circulation of 4 Virus Serotypes among Children with
514 Undifferentiated Fever, Kenya, 2014-2017. Emerg Infect Dis. 2020;26(11):2638-50.
515 11. Tariq A, Khan A, Mutuku F, Ndenga B, Bisanzio D, Grossi-Soyster EN, et al.
516 Understanding the factors contributing to dengue virus and chikungunya virus
517 seropositivity and seroconversion among children in Kenya. PLoS Negl Trop Dis.
518 2024;18(11):e0012616.
519 12. Girard M, Nelson CB, Picot V, Gubler DJ. Arboviruses: A global public health
520 threat. Vaccine. 2020;38(24):3989-94.
521 13. Gould E, Pettersson J, Higgs S, Charrel R, de Lamballerie X. Emerging
522 arboviruses: Why today? One Health. 2017;4:1-13.
523 14. Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV.
524 Dengue and dengue haemorrhagic fever. The lancet. 1998;352(9132):971-7.
525 15. Marchi S, Trombetta CM, Montomoli E. Emerging and re-emerging arboviral
526 diseases as a global health problem. Public Health: Emerging and Re-emerging
527 Issues United Kindgom: IntechOpen. 2018:25-46.
528 16. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.
529 Seroprevalence of chikungunya virus (CHIKV) infection on Lamu Island, Kenya,
530 October 2004. The American journal of tropical medicine and hygiene.
531 2008;78(2):333-7.
532 17. De Rivera IL, Parham L, Murillo W, Moncada W, Vazquez S. Humoral immune
533 response of dengue hemorrhagic fever cases in children from Tegucigalpa, Honduras.
534 The American journal of tropical medicine and hygiene. 2008;79(2):262-6.
535 18. Watson JT, Pertel PE, Jones RC, Siston AM, Paul WS, Austin CC, et al. Clinical
536 characteristics and functional outcomes of West Nile fever. Annals of Internal
537 Medicine. 2004;141(5):360-5.

538 19. Feldstein LR, Rowhani-Rahbar A, Staples JE, Weaver MR, Halloran ME, Ellis
539 EM. Persistent arthralgia associated with chikungunya virus outbreak, US Virgin
540 Islands, December 2014–February 2016. Emerging infectious diseases.
541 2017;23(4):673.
542 20. Wise EL. Metagenomic identification and characterisation of emerging and re-
543 emerging viruses causing disease in febrile patients: University of Plymouth; 2020.
544 21. Vu DM, Mutai N, Heath CJ, Vulule JM, Mutuku FM, Ndenga BA, et al.
545 Unrecognized Dengue Virus Infections in Children, Western Kenya, 2014-2015.
546 Emerg Infect Dis. 2017;23(11):1915-7.
547 22. Suchi NK, Mohammed HI, Ademola AO, Rinmecit PG. Parallel and concurrent
548 infection of Dengue virus and Plasmodium falciparum among patients with febrile
549 illnesses attending Bingham University Health Centre, Karu, Nigeria. Int J Trop Dis
550 Health. 2020;41:45-51.
551 23. Jentes ES, Robinson J, Johnson BW, Conde I, Sakouvougui Y, Iverson J, et al.
552 Acute arboviral infections in Guinea, west Africa, 2006. The American journal of
553 tropical medicine and hygiene. 2010;83(2):388.
554 24. Budodo RM, Horumpende PG, Mkumbaye SI, Mmbaga BT, Mwakapuja RS,
555 Chilongola JO. Serological evidence of exposure to Rift Valley, Dengue and
556 Chikungunya Viruses among agropastoral communities in Manyara and Morogoro
557 regions in Tanzania: A community survey. PLoS Neglected Tropical Diseases.
558 2020;14(7):e0008061.
559 25. Awando JA, Ongus JR, Ouma C, Mwau M. Seroprevalence of anti-dengue virus
560 2 serocomplex antibodies in out-patients with fever visiting selected hospitals in rural
561 parts of western Kenya in 2010-2011: a cross sectional study. Pan African Medical
562 Journal. 2014;16(1).

563 26. Sutherland LJ, Cash AA, Huang YJ, Sang RC, Malhotra I, Moormann AM, et al.
564 Serologic evidence of arboviral infections among humans in Kenya. Am J Trop Med
565 Hyg. 2011;85(1):158-61.
566 27. Hortion J, Mutuku FM, Eyherabide AL, Vu DM, Boothroyd DB, Grossi-Soyster
567 EN, et al. Acute Flavivirus and Alphavirus Infections among Children in Two Different
568 Areas of Kenya, 2015. Am J Trop Med Hyg. 2019;100(1):170-3.
569 28. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al.
570 High rates of o'nyong nyong and Chikungunya virus transmission in coastal Kenya.
571 PLoS Negl Trop Dis. 2015;9(2):e0003436.
572 29. Vu DM, Banda T, Teng CY, Heimbaugh C, Muchiri EM, Mungai PL, et al.
573 Dengue and West Nile Virus Transmission in Children and Adults in Coastal Kenya.
574 Am J Trop Med Hyg. 2017;96(1):141-3.
575 30. Grossi-Soyster EN, Cook EAJ, de Glanville WA, Thomas LF, Krystosik AR, Lee
576 J, et al. Serological and spatial analysis of alphavirus and flavivirus prevalence and
577 risk factors in a rural community in western Kenya. PLoS Negl Trop Dis.
578 2017;11(10):e0005998.
579 31. Bundo K, Igarashi A. Antibody-capture ELISA for detection of immunoglobulin
580 M antibodies in sera from Japanese encephalitis and dengue hemorrhagic fever
581 patients. J Virol Methods. 1985;11(1):15-22.
582 32. Igarashi A. Technical Manual of Arbovirus Study. Nagasaki University Institute
583 of Tropical Medicine. 2000;8:14.
584 33. Inziani M, Adungo F, Awando J, Kihoro R, Inoue S, Morita K, et al.
585 Seroprevalence of yellow fever, dengue, West Nile and chikungunya viruses in
586 children in Teso South Sub-County, Western Kenya. Int J Infect Dis. 2020;91:104-10.
587 34. Ng RJ, Chong ZL, Abdul Mutalip MH, Ng CW. Dengue Seroprevalence and
588 Factors Associated with Dengue Seropositivity in Petaling District, Malaysia. Int J
589 Environ Res Public Health. 2022;19(12).

590 35. Ma J, Xu N, Xu Y, Huang ZYX, Chen C, Wang YXG. Impacts of Urbanization
591 and Habitat Characteristics on the Human Risk of West Nile Disease in the United
592 States. Biology (Basel). 2025;14(3).
593 36. Neiderud CJ. How urbanization affects the epidemiology of emerging infectious
594 diseases. Infect Ecol Epidemiol. 2015;5:27060.
595 37. Jaramillo GI, Robledo PC, Mina NJ, Munoz JA, Ocampo CB. Comparison of
596 the efficacy of long-lasting insecticidal nets PermaNet(R) 2.0 and Olyset(R) against
597 Anopheles albimanus under laboratory conditions. Mem Inst Oswaldo Cruz.
598 2011;106(5):606-12.
599 38. Niewiesk S. Maternal antibodies: clinical significance, mechanism of
600 interference with immune responses, and possible vaccination strategies. Front
601 Immunol. 2014;5:446.
602
603

Authorship Contributions

Conceptualization and design of the study

M. Inziani, M. Mwau.

Methodology

M. Inziani, S. Inoue, M. Mwau

Acquisition of data/Data curation

M. Inziani, S. Inoue, M. Mwau

Formal Analysis and interpretation of data

M. Inziani, M. Kerubo, S. Mango, J. Kilonzo, M. Mwau

Visualization

M. Inziani, M. Kerubo, J. Kilonzo, A. Ndirangu, M. Mwau

Validation

M. Inziani, S. Mango, M. Kerubo, J. Kilonzo, A. Ndirangu, M. Mwau

Project administration

M. Mwau, S. Inoue, K. Morita

Resources

M. Mwau, K. Morita

Funding Acquisition

M. Mwau, K. Morita

Investigation

M. Inziani, S. Inoue, M. Mwau

Supervision:

M. Inziani, M. Mwau, S. Inoue, K. Morita

Drafting the original manuscript

M. Inziani, D. Oigara, S. Mango, E. Njeri, J. Kilonzo, M. Kerubo, S. Ayoro, D. Oigara, A. Ndirangu, M. Kavurani, M. Mwau

Manuscript - review & editing

M. Inziani, J. Kilonzo, M. Kerubo, S. Mango, M. Kavurani, A. Ndirangu, E. Njeri, S. Ayoro, D. Oigara, S. Inoue, K. Morita, M. Mwau

Approval of the version of the manuscript to be published:

M. Inziani, J. Kilonzo, M. Kerubo, S. Mango, M. Kavurani, A. Ndirangu, E. Njeri, S. Ayoro, D. Oigara, S. Inoue, K. Morita, M. Mwau.

Funding Sources

This work was supported by Kenya Medical Research Institute, Nairobi, Kenya and the Department of Virology, Nagasaki University Institute of Tropical Medicine, Nagasaki, Japan.

The study sponsors had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.

Conflict of Interest

The authors have no conflict of interest to declare.